Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Altor BioScience

Tracked across 20 events · 192 articles · First seen Apr 01, 2026 · Last active Sep 18, 2026

Sentiment
32
Attention
4
Events
20
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 75
Business
Impact: Altor BioScience has licensed vaccine technology from the United States — Centers for Disease Control and Prevention>>> and is developing an injectable rotavirus vaccine, which could significantly expand its market presence and contribute to global health.
Jun 09, 2026 · 6 articles
4 70
Business
Impact: Altor BioScience is hosting a Capital Markets Day to showcase its commercial momentum for MagnetOs and its plans for scalable growth, aiming to increase enterprise value and support long-term success.
Jun 17, 2026 · 6 articles
4 70
Tech
Impact: Altor BioScience announced the initiation of the final stage of its PF614-MPAR-102 clinical study, which is a significant step in the development of its novel opioid overdose-protection technology. This could lead to a new standard for opioid safety and expand its market reach.
Jun 26, 2026 · 6 articles
4 20
Business
Impact: Altor BioScience announced the pricing of a public offering of 10,000,000 shares of its common stock at $15.00 per share, expecting to raise $150.0 million. This capital will fund clinical trials, preclinical studies, manufacturing, and other general corporate purposes, which is positive for its operations and growth.
Jun 03, 2026 · 12 articles
4 80
Regulatory
Impact: Altor BioScience secured KRW 300 billion in financing from the Canada — Canada Growth Fund, which will accelerate the development of its pneumococcal vaccine candidate GBP410 and enhance its manufacturing capabilities. This funding strengthens its position in the global vaccine market and contributes to Korea's vaccine sovereignty.
May 29, 2026 · 6 articles
4 75
Business
Impact: Altor BioScience>>> is transferring its vaccine technology and manufacturing know-how to Venezuelan Petroleum Company>>> as part of a strategic expansion into Latin America, securing preferential negotiation rights for future vaccine products.
May 25, 2026 · 9 articles
4 75
Tech
Impact: Altor BioScience is leading the ROTOR project, developing an AI-powered platform for vaccine development, which enhances its R&D capabilities and global standing in the biotechnology sector.
Jul 02, 2026 · 7 articles
4 80
Business
Impact: Altor BioScience is the acquirer, becoming a fully integrated seed company. This acquisition enhances its commercial capabilities and market position, likely boosting investor confidence and growth prospects.
Jul 28, 2026 · 6 articles
2 10
Business
Impact: Altor BioScience is the issuer of the offering, raising $300 million to fund R&D and expansion. The capital raise supports growth but dilutes existing shareholders.
Aug 04, 2026 · 6 articles
2 40
Tech
Impact: Altor BioScience is the sponsor of the Phase 1b trial, advancing its RSM01 candidate into pediatric development. This strengthens its pipeline and positions it in the RSV antibody market.
Jul 20, 2026 · 7 articles
2 10
Business
Altor BioScience, Inc. (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases, commenced and then priced an underwritten public offering of 5,769,231 shares of its common stock at $26.00 per…
Impact: Altor BioScience is the issuer of the offering, raising approximately $150 million in gross proceeds to fund its pipeline and general corporate purposes. The raise bolsters its cash position but dilutes existing shareholders.
Sep 10, 2026 · 7 articles
2 25
Business
Altor BioScience Corporation announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company. Under the agreement, Twist will provide antibody characterization data services for TuneLab, including for…
Impact: Altor BioScience is the primary commercial beneficiary, supplying antibody characterization data services to TuneLab users and gaining access to a broader AI drug discovery ecosystem. The agreement could support its data-services revenue growth and strengthen its competitive position in antibody discovery.
Sep 16, 2026 · 6 articles
2 30
Tech
Impact: Altor BioScience is collaborating with SciBase on the DETECT-AD study, which is the first study through their partnership, potentially benefiting its research and development efforts.
Jun 10, 2026 · 7 articles
4 -20
Tech
Impact: Altor BioScience>>> sells NAD+ supplements, and its senior vice president, Andrew Shao>>>, downplayed the impact of the new study, emphasizing tissue-level NAD+ decline.
May 23, 2026 · 6 articles
2 10
Business
Impact: Altor BioScience is a contract research organisation involved in the preclinical studies, potentially gaining revenue from the project.
Jul 28, 2026 · 6 articles
2 0
Business
Impact: Altor BioScience is mentioned through its CEO, Vương Triều, who commented on the partnership between TechForce Robotics and Oncotelic Therapeutics.
Jun 01, 2026 · 6 articles
0 0
Business
Ipsen, a French biopharmaceutical company listed on Euronext Paris Paris (IPN) and through a US ADR program (IPSEY), announced on 18 September 2026 the co-optation of Mariette Finet as a Director to its Board of…
Impact: Altor BioScience is a former board seat of Finet; mentioned only as background on her experience.
Sep 18, 2026 · 7 articles
4 0
Business
Apr 01, 2026 · 64 articles
4 0
Business
Jun 15, 2026 · 6 articles
3 0
Tech
Jun 12, 2026 · 6 articles
Jaeyong Ahn ↔ Altor BioScience
Jaeyong Ahn ↔ Altor BioScience
ERGEN INTELLIGENCE
Track Altor BioScience live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.